Karim Dabbagh was appointed President and CEO of Second Genome in 2018, which he joined as the Chief Scientific Officer in 2014. Prior to that, he served as Vice President of R&D at Pfizer where he led the Immunoregulation department, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. At Pfizer, he also led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas. Before joining Pfizer, Karim was the founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease. Leading to that, Karim spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College, London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.

Susannah Cantrell joined Second Genome as their Chief Business Officer in 2020. Dr. Cantrell has over 20 years of industry experience across global pipeline strategy, sales, operations, marketing and new product commercialization. Her experience covers multiple therapeutic areas including cell therapy, oncology, inflammation, anti-infectives, cardiology, neurology and endocrinology. She most recently served as EVP and Chief Commercial Officer at Tricida for 2 years, where she led the buildout of a full U.S. focused commercial organization including marketing, sales, market access, trade, operations and training. Prior to Tricida, Dr. Cantrell was Vice President & Head of Global Commercial Strategy and Marketing Oncology at Gilead Sciences, Inc. where she was instrumental in leading and building its oncology and inflammation business from 2011 to 2019. While at Gilead, she led global marketing strategy and launch activities for the oncology and cell therapy portfolio. Prior to her time at Gilead, Dr. Cantrell held various senior level positions at Genentech/Roche from 2005 to 2011, including marketing, strategic business planning and sales. She participated in life-cycle management and the pre-launch and commercial launch of several products, including RITUXAN, HERCEPTIN, AVASTIN and TARCEVA. Dr. Cantrell also led the pre-launch and commercialization activities for Genentech’s BioOncology pipeline. Prior to Genentech, Dr. Cantrell held sales and marketing positions at GlaxoSmithKline, where she managed the anti-infective portfolio. Dr. Cantrell holds a BA in biology from Westminster College and a PhD in biochemistry from the University of Missouri-Columbia.

Preeti G. Lal joined Second Genome in 2021 as the Chief Scientific Officer. Dr. Lal has over 25 years of experience leading data science, translational medicine including all phases of clinical trials development, regulatory interactions with both the drug and device divisions of FDA, and companion diagnostics (Dx) programs.

Prior to Second Genome, she worked at several leading healthcare companies: Alladapt Immunotherapeutics where she led translational medicine and data science projects in multi food allergy indication, Roche Diagnostics where she worked on liquid biopsy and digital health, Gilead Sciences where she focused on clinical biomarkers and companion Dx across a range of therapeutic indications, Genentech where she led biomarker development work in atopic diseases such as asthma and on autoimmune diseases with a notable focus on leading a companion Dx program in an immunology indication, and CareDx where she used the knowledge of data science, bioinformatics and immunology to develop the diagnostic algorithm “AlloMap” containing multiple gene expression values approved under IVDMIA guidance by FDA as an aid in the management of heart transplant subjects and reduce routine heart biopsies. Following her Ph.D., she spent seven years at Incyte Genomics where she managed a bioinformatics group involved with data mining and usage of novel methods for the discovery of drug targets and biomarkers including secreted proteins and the analysis of laboratory data from cell-based assays. She worked on numerous pharma collaborations as the technical lead. She is a co-inventor on >150 patents.

Preeti obtained her Ph.D. in Immunology from the Medical University of South Carolina and MSc (Hons) in Microbiology from Bombay University, India. She did her fellowship in Tumor Biology at Stanford University where she worked on Astrocytoma and developing uses of the biomarker GFAP.

Todd DeSantis is Second Genome Co-founder and Vice-President of Informatics. Todd has 17 years of experience designing and implementing bioinformatics solutions for analyzing microbial community dynamics. At Lawrence Berkeley National Laboratory he led the development of novel microbiome assays and analysis pipelines as a Molecular Microbial Ecology Software Developer. He is the chief architect of GreengenesTM, an international effort to catalog global microbial diversity that provides microbial ecologists with reference databases for DNA quality assessment, alignment and classification. Todd also served as an analyst for the NIH Human Microbiome Project and has published over 60 scientific papers. At Second Genome, he manages all informatics work including identifying and recruiting microbiome scientist leaders, integration of multi-omics pipelines, cloud deployment for big-data analytics, and therapeutic pathway discovery.

Pete Roddy currently serves as a finance and accounting consultant to Second Genome and other biopharmaceutical companies. Previously, he served as SVP, Chief Accounting Officer of Cytokinetics, a biopharmaceutical company focused on impaired muscle function, from 2017 to 2019 and as a consultant since 2019. He was also Chief Financial Officer of Pain Therapeutics, which works in the neuroscience space, from 2002 to 2017. Earlier in his career, Mr. Roddy held a variety of senior management positions at a cardiovascular-focused biopharmaceutical company, COR Therapeutics, including SVP, Finance and Chief Financial Officer from 2000 and 2002. He also served as a member of the Board of Directors of Vermilion, from 2010 to 2016. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.

Laura Brege currently serves as a senior advisor to Second Genome. Ms. Brege also serves as senior advisor to BridgeBio Pharma (BBIO), a biotechnology company focused on creating medicines that target well-characterized genetic diseases. Previously, Ms. Brege was EVP and Chief Operating Officer of Onyx Pharmaceuticals (ONXX), an oncology biotechnology company acquired by Amgen, and Chief Financial Officer of COR Therapeutics (CORR), a biotechnology company specializing in cardiovascular disease, acquired by Millennium Pharmaceuticals. Earlier, Ms. Brege served as Chief Financial Officer of Flextronics, (FLEX) a global technology manufacturer, and as Treasurer of The Cooper Companies (COO).

Ms. Brege currently serves on the Board of Directors of several public life science companies, including Acadia Pharmaceuticals (ACAD), Pacira Pharmaceuticals (PCRX) and Mirum Pharmaceuticals (MIRM). She is also Chair of the international non-profit educational organization, CIEE. Ms. Brege earned a B.A. from Ohio University and an M.B.A. from the University of Chicago.